Linda R. Duska, MD, MPH

home / authors / linda-r-duska-md-mph

Linda R. Duska, MD, MPH, is a gynecologic oncologist at the University of Virginia Health.

Articles

Linda R. Duska, MD, MPH

Dr Duska on the Efficacy of Pembrolizumab Plus Concurrent CRT in Advanced Cervical Cancer

Linda R. Duska, MD, MPH
March 31st 2025

Linda R. Duska, MD, MPH, discusses OS and PFS2 outcomes with concurrent pembrolizumab and chemoradiotherapy in high-risk advanced cervical cancer.

Read More

Dr. Duska on Primary Debulking Surgery in Ovarian Cancer

Dr. Duska on Primary Debulking Surgery in Ovarian Cancer

Linda R. Duska, MD, MPH
February 8th 2020

Linda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.

Read More

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

Linda R. Duska, MD, MPH
January 29th 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Read More

Dr. Duska on Neoadjuvant Chemo Vs Upfront Surgery in Ovarian Cancer

Dr. Duska on Neoadjuvant Chemo Vs Upfront Surgery in Ovarian Cancer

Linda R. Duska, MD, MPH
August 28th 2019

Linda R. Duska, MD, discusses neoadjuvant chemotherapy versus upfront surgical debulking in patients with advanced ovarian cancer.

Read More

Latest Updated Articles

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial